A61K 51/1051
The tumor cell being from breast
Official title: {the tumor cell being from breast, e.g. the antibody being herceptin}
A61K51/1051 (The tumor cell being from breast) appears on 118 US grants and 204 published applications in this corpus.
Search patents in A61K- Granted patents
- 118
- Published applications
- 204
- Assignees
- 94
- Inventors
- 328
- Latest grant
- 28 Oct 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1985 | 1 | 0 |
| 1986 | 1 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 2 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 1 | 0 |
| 1996 | 1 | 0 |
| 1997 | 1 | 0 |
| 1998 | 2 | 0 |
| 1999 | 3 | 0 |
| 2000 | 1 | 0 |
| 2001 | 4 | 0 |
| 2002 | 0 | 2 |
| 2003 | 0 | 4 |
| 2004 | 2 | 10 |
| 2005 | 2 | 8 |
| 2006 | 1 | 7 |
| 2007 | 4 | 4 |
| 2008 | 6 | 4 |
| 2009 | 6 | 15 |
| 2010 | 0 | 4 |
| 2011 | 6 | 5 |
| 2012 | 3 | 9 |
| 2013 | 4 | 6 |
| 2014 | 4 | 7 |
| 2015 | 4 | 7 |
| 2016 | 4 | 11 |
| 2017 | 8 | 11 |
| 2018 | 5 | 10 |
| 2019 | 8 | 10 |
| 2020 | 6 | 12 |
| 2021 | 3 | 9 |
| 2022 | 8 | 15 |
| 2023 | 6 | 9 |
| 2024 | 7 | 8 |
| 2025 | 4 | 10 |
| 2026 | 0 | 7 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Nanobody based imaging and targeting of ECM in disease and development28 Oct 2025US 12,454,576 B2Children's Medical Center Corporation
- Radiolabelled antibody fragments for use in treating cancer14 Oct 2025US 12,440,586 B2Vrije Universiteit Brussel
- Cysteine linked nanobody dimers12 Aug 2025US 12,384,835 B2Ablynx N. V.
- Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer25 Mar 2025US 12,258,339 B2Cornell University
- Anti-B7-H4 antibodies and immunoconjugates5 Nov 2024US 12,134,649 B2Genentech, Inc.
- Combined Therapy with Nanoparticles and Radiopharmaceuticals3 Sep 2026US 2026/0256963 A1Centre National De La Recherche Scientifique
- Method for producing radioactive pharmaceutical composition2 Jul 2026US 2026/0183436 A1Nihon Medi-Physics Co., Ltd.
- Vhh antibody conjugates with heteroaryl chelators2 Jul 2026US 2026/0183437 A1Abdera Therapeutics Inc.
- Radiopharmaceutical mofs for medical imaging4 Jun 2026US 2026/0151522 A1Node Pharma AS
- Mofs with beta-emitters for radiotherapy30 Apr 2026US 2026/0115336 A1Node Pharma AS
Most cited
By later US patents
- RS7 antibodies134US 7,238,785 B2Immunomedics, Inc. · 2007
- Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides112US 6,309,636 B1Cancer Research Institute of Contra Costa · 2001
- Monoclonal antibodies reactive with human breast cancer79US 4,612,282 AThe United States of America, as represented by the Secretary, Department of Health and Human Services · 1986
- Process for producing monoclonal antibodies reactive with human breast cancer76US 4,522,918 A1985
- Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy57US 4,939,240 AHealth Research, Inc. · 1990